Breaking news

Kailera’s Bold Bet: Skipping The Lab, Racing To Market With China’s Ozempic Rivals

by News Editor

While Big Pharma pours billions into obesity drug R&D, a new biotech startup is taking a shortcut: licensing ready-to-go therapies from China. Kailera Therapeutics, launched with $400 million from Bain Capital, Atlas Venture, and RTW Investments, is fast-tracking four obesity drugs developed by Jiangsu Hengrui — one of China’s pharmaceutical heavyweights.

The playbook? Bypass years of early-stage research. “We saw next-gen GLP-1 therapies that could leapfrog existing options,” says Dr. Amir Zamani, Bain’s life sciences partner who spearheaded the deal. One injectable candidate from Hengrui showed 59% of patients losing 20 %+ body weight in Phase II trials, with mild side effects. Even more promising: two of the licensed drugs are pills, a potential game-changer in a market currently dominated by injectables.

With global obesity drug sales projected to hit $131 billion by 2028, Kailera aims to move fast. Leading the charge is biotech veteran Ron Renaud, who’s sold three companies for a combined $16 billion. “We likely have the most advanced and diverse weight-loss pipeline outside Big Pharma,” he says. The goal is to bring the first drug to market by 2030 — a rapid timeline thanks to Hengrui’s head start.

China’s rise as a pharmaceutical R&D hub is reshaping the biotech map. Over a third of molecules licensed by Western firms now originate there. U.S. firms have spent $8.1 billion since 2020 licensing Chinese-developed drugs — a stark contrast to just $536 million in the previous five years.

Kailera is betting this east-west fusion can deliver blockbuster results. With 100 million obese adults in the U.S. alone — not to mention global demand — the addressable market is massive. “This isn’t a one-drug race,” Renaud says. “It’s going to take an entire arsenal.”

To prep for launch, Kailera has added top-tier talent: Scott Wasserman, former cardiovascular lead at Amgen, is chief medical officer; Jamie Coleman, who led Zepbound’s commercial rollout at Lilly, now heads marketing.

Whether Kailera becomes the next independent giant or is eventually snapped up by Big Pharma, as Renaud’s previous ventures were, it’s already a standout in the white-hot weight-loss drug race.

Greek Tankers Transit Hormuz As Shipping Risks Rise In Gulf And Black Sea

by THEFUTURE.TEAM

Two tankers linked to George Prokopiou passed through the Strait of Hormuz as regional tensions continue to affect shipping routes in the Gulf.

Safe Passage Through Hormuz

The tanker Smyrni, operated by Dynacom Tankers Management, was observed off the coast of Mumbai on Saturday morning after its earlier positioning in the Persian Gulf. The vessel, like its predecessor Shenlong, temporarily disabled its transponder during transit, a common practice in these narrow channels under uncertain conditions.

Robust Market Commitments

Despite reduced shipping traffic through the strait, Dynacom has continued expanding its fleet. The company recently ordered four additional VLCC tankers from Hengli Heavy Industry. Each vessel will have a capacity of 300,000 deadweight tonnes. With the new order, Dynacom’s VLCC program in Chinese shipyards now totals 16 vessels.

Security Incident In The Black Sea

In a separate incident, the Greek-flagged tanker Maran Homer sustained minor damage near Novorossiysk in the Black Sea. The vessel is operated by Maran Tankers Management, part of the shipping group controlled by Maria Angelicoussis.

Reports indicated the ship was struck by a missile or drone about 14 nautical miles from the port. The crew of 24, including Greek, Filipino and Romanian sailors, was not injured. The vessel, which was not carrying cargo, continued sailing under its own power.

Uol
The Future Forbes Realty Global Properties
eCredo
Aretilaw firm

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter